StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

Mon, 31 Aug 2026 06:50:33 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $115.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).

The analyst commented: "Arrowhead’s (ARWR; Buy; Trucchio) pooled SHASTA-3/4 analysis showed that quarterly 25mg plozasiran reduced total adjudicated acute pancreatitis (AP) events by 78%, with a rate ratio of 0.22 (95% CI, 0.07-0.67), 4.1% absolute risk reduction (ARR) and one-year number needed to treat (NNT) of 24. TRYNGOLZA produced an 85% reduction, rate ratio of 0.15, 5.2% ARR and NNT of 20 in pooled CORE/CORE2. Every broad-population AP measure numerically favors TRYNGOLZA—85% vs. 78% relative reduction, 5.2% vs. 4.1% ARR and NNT 20

JPMorgan Reiterates Overweight Rating on Ionis Pharmaceuticals (IONS)

Mon, 31 Aug 2026 02:41:46 -0400

JPMorgan analyst Jessica Fye reiterated an Overweight rating and $76.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS)

The analyst comments: “Coming off Tryngolza competitor plozasiran’s detailed phase III data in severe hypertriglyceridemia (sHTG), we continue to see efficacy for these products as extremely similar with ploza’s advantage mainly on dosing convenience (quarterly vs monthly). We also see a slight edge for ploza on liver enzymes, platelets, and liver fat, though we note that these are not viewed as significant to Tryngolza’s profile to begin with. Looking ahead, we are watching Tryngolza’s early launch in sHTG and also monitoring ION775, IONS’s siRNA

Alnylam stock drops on rival heart trial: Why analysts see core business safe

Fri, 28 Aug 2026 08:25:50 -0400

Investing.com -- A major clinical trial failure in heart disease is reverberating across Wall Street, wiping hundreds of millions of dollars off the market value of RNA-therapeutics pioneer Alnylam Pharmaceuticals before the opening bell on Friday.

Shares of Alnylam (NASDAQ: ALNY) fell nearly 4.9% in pre-market trading following the full presentation of data from a rival drug trial at the European Society of Cardiology Congress in Munich. The detailed results from AstraZeneca and Ionis Pharmaceuticals’ Phase 3 CARDIO-TTRansform trial—evaluating their drug Wainua in transthyretin amyloid cardiomyopathy (ATTR-CM)—confirmed an earlier top-line failure, but alarmed investors with an

Alnylam stock drops on rival heart trial: Why analysts see core business safe

Fri, 28 Aug 2026 08:25:50 -0400

Alnylam stock drops on rival heart trial: Why analysts see core business safe

Fri, 28 Aug 2026 08:25:50 -0400

Alnylam stock drops on rival heart trial: Why analysts see core business safe

Fri, 28 Aug 2026 08:25:50 -0400

Alnylam stock drops on rival heart trial: Why analysts see core business safe

Fri, 28 Aug 2026 08:25:50 -0400

Alnylam stock drops on rival heart trial: Why analysts see core business safe

Fri, 28 Aug 2026 08:25:50 -0400

Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)

Mon, 24 Aug 2026 06:40:24 -0400

Canaccord analyst Gary Nachman reiterated a Buy rating and $95.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS).

The analyst commented: "We recently hosted in-person investor meetings in LA with IONS, including Brett Monia (CEO), Holly Kordasiewicz (CDO), and Julie Tepper (IR), with management enthusiastic about several upcoming catalysts that could drive good value. IONS has continued to execute very well in its transition to becoming a commercial organization, now with 2 wholly owned products approved for 3 indications (Tryngolza for FCS/sHTG, Dawnzera for HAE) that are all ramping well. Recent launch of Tryngolza for sHTG remains the key focus for investors

Ionis to present olezarsen and ION775 data at ESC Congress 2026

Thu, 20 Aug 2026 07:00:23 -0400

Ionis Pharmaceuticals (Nasdaq: IONS) announced it will present new data on treatments for severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026, scheduled for August 28–31 in Munich.

Presentations will include one-year data from an open-label, long-term extension study of TRYNGOLZA (olezarsen), which received U.S. Food and Drug Administration approval for sHTG in June 2026. The drug is indicated as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG, defined as triglyceride levels of 500 mg/dL or higher.

Ionis will also present Phase 1 data for ION775, an investigational siRNA therapy targeting

Ionis to present olezarsen and ION775 data at ESC Congress 2026

Thu, 20 Aug 2026 07:00:23 -0400

Ionis will also present Phase 1 data for ION775, an investigational siRNA therapy targeting

Ionis to present olezarsen and ION775 data at ESC Congress 2026

Thu, 20 Aug 2026 07:00:23 -0400

Ionis will also present Phase 1 data for ION775, an investigational siRNA therapy targeting

Ionis to present olezarsen and ION775 data at ESC Congress 2026

Thu, 20 Aug 2026 07:00:23 -0400

Ionis will also present Phase 1 data for ION775, an investigational siRNA therapy targeting

Ionis to present olezarsen and ION775 data at ESC Congress 2026

Thu, 20 Aug 2026 07:00:23 -0400

Ionis will also present Phase 1 data for ION775, an investigational siRNA therapy targeting

Ionis to present olezarsen and ION775 data at ESC Congress 2026

Thu, 20 Aug 2026 07:00:23 -0400

Ionis will also present Phase 1 data for ION775, an investigational siRNA therapy targeting

Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026